4CPS-115 Nabpaclitaxel plus gemcitabine versus folfirinox in metastatic pancreatic cancer: real-world data experience | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Section 4: Clinical pharmacy services

4CPS-115 Nabpaclitaxel plus gemcitabine versus folfirinox in metastatic pancreatic cancer: real-world data experience

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Moreno Ramos C, Gil Sierra M, Martínez Díaz C

4CPS-115 Nabpaclitaxel plus gemcitabine versus folfirinox in metastatic pancreatic cancer: real-world data experience

European Journal of Hospital Pharmacy 2022;29:A68.